Title:
抗ＣＤ１９免疫療法によりがんを処置するための組成物および方法
Document Type and Number:
Japanese Patent JP7035170
Kind Code:
B2
Abstract:
Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
More Like This:
| JP2023510121 | Anti-Muc1 Compositions and Methods of Use |
| JP2023506454 | Cytokine-based bioactivating agents and their uses |
| JP2022084893 | MODIFIED BACTERIOPHAGE |
Inventors:
Schneider, Dina
Orentas, Limas Jay
Doroprik, Boro
Dimitrov, Dimita S
Chu, Zhong Yui
Orentas, Limas Jay
Doroprik, Boro
Dimitrov, Dimita S
Chu, Zhong Yui
Application Number:
JP2020515262A
Publication Date:
March 14, 2022
Filing Date:
September 14, 2018
Export Citation:
Assignee:
LENTIGEN TECHNOLOGY, INC.
International Classes:
C12N15/62; A61K35/17; A61K39/395; A61P35/00; A61P35/02; C07K19/00; C12N5/0783; C12N5/10; C12N15/12; C12N15/13
Domestic Patent References:
| JP2017526370A |
Other References:
J. Immunother. Cancer,2017年,5:42
Attorney, Agent or Firm:
Fukami patent office
Previous Patent: Hybrid dynamic inductance device for superconducting quantum computing
Next Patent: Pore formation in the substrate
Next Patent: Pore formation in the substrate